Investors seeking stocks with explosive growth potential should consider the biotech industry. Drugmakers can experience ...

A study identified two key genes (CTNNA1 and BCL2L13) as suppressors in spread of colorectal cancer, revealing new strategies ...

Casgevy, now a "national priority" drug, helped kids with sickle cell and thalassemia, results which may help toward a label ...

Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, has published new research in ...

The problem, Zaaijer explained, is that algorithms used in precision medicine models overwhelming are built on DNA with ...

Cardiologist and Men's Health advisory board member Christopher Kelly, MD, says this treatment is "approaching magic" for ...

The launch of BIRSA 101 marks a major breakthrough in CRISPR gene-editing technology, positioning India to deliver affordable ...

CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the most oversold biotech stocks to invest in. Following the company’s third ...

CRISPR Therapeutics (NASDAQ:CRSP) gains visibility as biotechnology activity aligns with broader movements across the Nasdaq ...

Urnov is a professor of molecular therapeutics at the University of California, Berkeley, and a director at its Innovative Genomics Institute. In May, news broke of a biomedical first: the on-demand ...

A single infusion of an experimental gene-editing drug appears safe and effective for cutting cholesterol, possibly for life, according to a small early study released Saturday. The study, which ...